Taken together, our novel data suggest that pharmacological blockade of S100A8/A9 may represent a promising cardioprotective strategy in cancer patients with history of diabetes, thus restoring the therapeutic value of doxorubicin in these patients. This evidence concerns the gene S100A8 and diabetes mellitus.